Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Ulcerative Colitis: Update Bulletin [June 2017]

Product Code:
596200728
Publication Date:
June 2017
Format:
PDF
Price:
€975

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on: Takeda announcing the presentation of real-world analyses for Entyvio (vedolizumab) in UC; InDex Pharmaceuticals announcing that it has enrolled the first patient in the Phase IIb CONDUCT trial for Kappaproct (cobitolimod); as well as Amgen announcing the European Commission approval of Amgevita (biosimilar adalimumab) in all available indications, including moderate-to-severe UC.

Business Questions:

  • How do KOLs regard real-world analyses of Entyvio?
  • What potential threats could Entyvio face in the future?
  • What are KOL views on Kappaproct and how would this agent be used if approved?
  • What impact is Amgevita/Amjevita expected to have on the UC anti-TNF market?
  • According to KOLs, which anti-TNF biosimilar is expected to have the most success in UC?



customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved